Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

301.00DKK
22 Jun 2018
Change (% chg)

kr.1.80 (+0.60%)
Prev Close
kr.299.20
Open
kr.299.00
Day's High
kr.301.70
Day's Low
kr.297.20
Volume
2,917,827
Avg. Vol
3,100,885
52-wk High
kr.354.80
52-wk Low
kr.260.20

Latest Key Developments (Source: Significant Developments)

Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight
Thursday, 21 Jun 2018 

June 20 (Reuters) - Novo Nordisk A/S ::ORAL SEMAGLUTIDE SHOWS STATISTICALLY SIGNIFICANTLY GREATER REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO VICTOZA AND SITAGLIPTIN IN PIONEER 4 AND 7 TRIALS.PIONEER 4 ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING A NON-INFERIOR REDUCTION IN HBA1C.ORAL SEMAGLUTIDE PROVIDED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO PLACEBO..PLANS TO REPORT PIONEER 3 TRIAL COMPARING 3, 7 AND 14 MG ORAL SEMAGLUTIDE WITH 100 MG SITAGLIPTIN BEFORE END OF Q2 OF 2018.  Full Article

Novo Nordisk And Kallyope Collaborates To Discover New Obesity And Diabetes Drugs
Tuesday, 19 Jun 2018 

June 19 (Reuters) - NOVO NORDISK A/S ::SAYS KALLYOPE, INC AND NOVO NORDISK A/S TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A RESEARCH COLLABORATION AND OPTION AGREEMENT TO DISCOVER NOVEL PEPTIDE THERAPEUTICS TO TREAT OBESITY AND DIABETES.SAYS KALLYOPE WILL RECEIVE AN UPFRONT PAYMENT AND RESEARCH SUPPORT FOR ACTIVITIES CONDUCTED IN COLLABORATION.SAYS UNDER TERMS OF AGREEMENT, NOVO NORDISK HAS AN OPTION TO LICENSE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALISE UP TO SIX PRODUCTS DISCOVERED IN COLLABORATION.KALLYOPE WILL RECEIVE A LICENSE FEE IF NOVO NORDISK CHOOSES TO EXERCISE AN OPTION TO A THERAPEUTIC DISCOVERED AND VALIDATED IN THE JOINT RESEARCH PLAN AND POTENTIAL RESEARCH, DEVELOPMENT AND SALES MILESTONES.IN ADDITION, KALLYOPE WILL RECEIVE ROYALTIES ON WORLDWIDE PRODUCT SALES OF LICENSED PRODUCTS.  Full Article

Novo Nordisk Says Oral Semaglutide Shows Superior Improvement In HbA1c Vs Empagliflozin In Pioneer 2 Trial
Tuesday, 29 May 2018 

May 29 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK SAYS ORAL SEMAGLUTIDE SHOWS SUPERIOR IMPROVEMENT IN HBA1C VERSUS EMPAGLIFLOZIN IN PIONEER 2 TRIAL.NOVO NORDISK-TRIAL ACHIEVED PRIMARY OBJECTIVE DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN HBA(1C) WITH ORAL SEMAGLUTIDE COMPARED TO EMPAGLIFLOZIN.  Full Article

Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S
Thursday, 24 May 2018 

May 23 (Reuters) - Novo Nordisk A/S ::EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION.EPIGEN BIOSCIENCES SAYS CO WILL ALSO BE ELIGIBLE TO GET TIERED ROYALTIES AND MILESTONES ON WORLDWIDE SALES OF PRODUCTS THAT ARISE FROM COLLABORATION.  Full Article

Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme
Saturday, 5 May 2018 

May 4 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME.TODAY ENTERED INTO AN AGREEMENT TO PURCHASE 3,415,895 B SHARES OF A VALUE OF DKK 1,038 MILLION FROM NOVO HOLDINGS A/S.TRANSACTION PART OF CO'S 2018 SHARE REPURCHASE PROGRAMME OF UP TO DKK 14.0 BILLION TO BE EXECUTED DURING 12 MONTHS PERIOD FROM 1 FEBRUARY 2018.TRANSACTION IN LINE WITH ANNOUNCEMENT ON 2 MAY THAT NOVO HOLDINGS A/S INTENDS TO MAINTAIN ITS OWNERSHIP OF CO'S SHARE CAPITAL AROUND 28%.  Full Article

Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018
Wednesday, 2 May 2018 

May 2 (Reuters) - NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS::SALES OF OZEMPIC DIABETES DRUG IS EXPECTED TO REACH AT LEAST DKK 1 BILLION IN 2018.VICTOZA DIABETES DRUG STILL LOSING MARKET SHARE TO ELI LILLY'S TRULICITY, ALBEIT AT LOWER PACE.  Full Article

Novo Nordisk Beats Q1 Expectations; Lifts 2018 Guidance A Tad
Wednesday, 2 May 2018 

May 2 (Reuters) - NOVO NORDISK A/S SAYS::OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018.2018 OPERATING PROFIT GROWTH IS NOW EXPECTED TO BE 2-5% COMPARED WITH PRIOR GUIDANCE OF 1-5%.Q1 EBIT 12.4 BILLION DKK VERSUS 11.8 BILLION DKK SEEN IN REUTERS POLL.Q1 SALES 26.9 BILLION DKK VERSUS 26.7 BILLION DKK SEEN IN REUTERS POLL.2018 SALES GROWTH IS NOW EXPECTED TO BE 3-5% MEASURED IN LOCAL CURRENCIES COMPARED WITH PRIOR GUIDANCE OF 2-5%.Q1 NET PROFIT 10.8 BILLION DKK VERSUS 10.1 BILLION DKK SEEN IN REUTERS POLL.2018 SALES GROWTH AND OPERATING PROFIT GROWTH REPORTED IN DANISH KRONER ARE NOW EXPECTED TO BE 6 AND 9 PERCENTAGE POINTS LOWER THAN IN LOCAL CURRENCIES, RESPECTIVELY.CEO SAYS "BASED ON PERFORMANCE OF OUR KEY PRODUCTS VICTOZA, TRESIBA AND SAXENDA, WE DELIVERED SOLID UNDERLYING GROWTH IN BOTH SALES AND OPERATING PROFIT IN FIRST THREE MONTHS OF 2018".EXPECTS SALES IN 2019 TO BE NEGATIVELY IMPACTED BY 1-2% AS A RESULT OF NEW REQUIREMENTS FOR MEDICARE PART D COVERAGE.  Full Article

Novo Nordisk Investigates Hypoglycaemia's Impact On Diabetes
Tuesday, 1 May 2018 

May 1 (Reuters) - NOVO NORDISK A/S SAYS::PARTICIPATES IN NEW RESEARCH PROJECT HYPO-RESOLVE TO INVESTIGATE HYPOGLYCAEMIA AND ITS IMPACT IN DIABETES.THE INTERNATIONAL CONSORTIUM AIMS TO PROVIDE EVIDENCE-BASED CLASSIFICATION OF HYPOGLYCAEMIA TO ACHIEVE BETTER TREATMENTS FOR PEOPLE LIVING WITH DIABETES.  Full Article

BP PLC Says Helge Lund To Be New Chairman
Thursday, 26 Apr 2018 

April 26 (Reuters) - BP PLC ::HELGE LUND TO BE NEW BP CHAIRMAN.BP PLC - APPOINTED HELGE LUND TO SUCCEED CARL-HENRIC SVANBERG AS CHAIRMAN OF BP..BP PLC - LUND WILL JOIN BP BOARD AS CHAIRMAN DESIGNATE AND A NON-EXECUTIVE DIRECTOR ON 1 SEPTEMBER 2018.BP PLC - LUND, WHO IS ALSO CHAIRMAN OF NOVO NORDISK AS IN DENMARK, WILL STAND DOWN WITH IMMEDIATE EFFECT FROM HIS DIRECTORSHIP AT SCHLUMBERGER.  Full Article

Xultophy Approved In Canada For Treatment Of Adults With Type 2 Diabetes
Thursday, 19 Apr 2018 

April 19 (Reuters) - Novo Nordisk A/S ::XULTOPHY APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES.  Full Article

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.